Skip to main content Skip to search Skip to main navigation

Why Nobody Wants ICH Q14 — And Why That’s Exactly the Problem

3 min. reading time | by Dr. Anamarija Ćurić, nuvalore GmbH  
Published in LOGFILE 13/2026 

The ICH Guideline Q14 “Analytical Procedure Development” was published in November 2023. This forward-looking and regulatory-savvy document builds upon the content of ICH Q2(R2) “Validation of Analytical Procedures” and incorporates elements from ICH Q8 “Pharmaceutical Development” and ICH Q9(R1) “Quality Risk Management.” Although this guideline holds great potential, it has received little attention in practice so far. Dr. Anamarija Curic explains the reasons behind this.


The big silence after publication

When the ICH Guideline Q14 came into force in the summer of 2024, the tone was clear: a paradigm shift, analytical Quality by Design, a lifecycle approach to methodologies, and scientific freedom. It sounded like a new beginning. Two years on, there is a striking silence. In the laboratories, business continues as usual.


Future-oriented, but non-binding 

ICH Q14 is perhaps the most elegant regulatory document of recent years, and at the same time one of the least prescriptive. The basic idea of distinguishing between a minimal and an enhanced development approach is a sound regulatory one. It takes into account product complexity, company size and risk profile. Yet this is precisely where its weakness lies. 

That's because in everyday GMP practice, a simple logic applies: if it doesn't result in a finding, it isn't a priority. ICH Q2(R2) is sufficient to ensure audit readiness. ICH Q14 does not offer any immediate compliance benefits, but ‘merely’ a long-term perspective. The key added value of ICH Q14 lies not in the present, but in the future: more robust methods, easier changes, less post-approval pain, and greater flexibility throughout the lifecycle. The benefits often only become apparent years later. 


Q14 is not suitable for established organisations

The guideline calls for integrated collaboration between development, quality control (QC), quality assurance (QA) and regulatory affairs. It requires statistical expertise that goes beyond linear models. It requires that methodological knowledge be nurtured like a product, rather than filed away like a test report.

In many companies, however, the reality is fragmented. Quality control is overburdened with operational tasks, development is out of sync with the rest of the organisation, and knowledge is lost whenever staff change. Within this system, ICH Q14 does not appear to be a help, but rather a source of discord. QC must be understood as a strategic function. QC should not treat analytical methods merely as testing tools, but as vehicles for process and product knowledge.


Q14 is too academic and out of touch with practice 

The strongest criticism levelled at ICH Q14 is that it contains too much theory, too much statistics and too little practical value. 

This criticism should be taken seriously. There is indeed a risk that Q14 will become stuck in PowerPoint design spaces and ATP texts without improving day-to-day laboratory practice. If poorly implemented, it becomes a paper exercise.

Yet this criticism misses the point. It is not Q14 that is academic, but rather that its implementation is often poorly executed. The guideline does not force over-engineering. On the contrary: it explicitly allows for minimal approaches. The problem is not the guideline. The problem is that it is either ignored or over-engineered, rather than being applied judiciously.


Q14 is not a tool. It is a mirror. 

So why does nobody want ICH Q14? 

Because it doesn’t deliver a quick win but requires a fundamental re-evaluation. And because it shows that analytical GMP is at a fork in the road. ICH Q14 is not a project that can simply be ‘introduced’.

It is a conceptual framework that helps organisations move forward.

Those who ignore it today may be acting efficiently in the short term. Those who need it tomorrow will wonder why they didn’t start yesterday.

The question is, when will ICH Q14 be needed? The question is, when will the cost of not using it exceed the effort required to implement it? And this calculation will be made sooner than many expect.


Do you have any questions or suggestions? Please contact us at: redaktion@gmp-verlag.de

Dr. Anamarija Ćurić

You may also be interested in the following articles:

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
News: EMA

EMA: Report on First Bilateral Meeting with APIC Published

The EMA has published the highlights of its first bilateral meeting with the Active Pharmaceutical Ingredients Committee (APIC). Topics included GMP oversight of API manufacturers, the reuse of recovered solvents and nitrosamine risks.
Read more
Save Time and Money when Qualifying a Blister Packaging Line

Save Time and Money when Qualifying a Blister Packaging Line

Qualifying a blister packaging line is not only technically demanding, but also time-consuming and costly. Here you will find important tips on how to organise your qualification process in a cost-effective yet gmp-compliant manner.

Read more
Previous
Next

Related Products

Skip product gallery
GMP Compliance Adviser

GMP Compliance Adviser

With an named user licence, one user can access the knowledge portal; with a corporate licence, any number of users can access it.Approx. 5,000 pages of practical GMP knowledge with illustrations and forms: Practical guidance for rapid implementation in the workplaceDetailed descriptions of GMP-compliant systemsInternational laws and guidelines Always up-to-date thanks to regular updates Download Advantages and Prices60+ Sample Documents In addition, the GMP Compliance Adviser contains more than 60 sample documents (MS Office) and practical examples that you can use.Sample SOPsSample FormsSample ReportsSample DocumentationChecklistsProcess Diagrams (Flowcharts)Practical Examples of QRM Application (e.g., Risk Analyses)Sample Documents for Qualification and ValidationCase StudiesWritten by more than 80 authors with hands-on experience directly linked to the industryA team of over 80 experts interpret regulatory requirements and describe how they are implemented in practice.The authors are experienced in the pharmaceutical industry, consulting, and government agencies.

delivery immediately after receipt of payment
€597.00 net excl. VAT
GMP Compliance Adviser | Free Demo Access

GMP Compliance Adviser | Free Demo Access

You will receive your login credentials via email. Throughout the week, you will receive further information about GMP Compliance Adviser directly in your inbox. Customer support is available to assist you at any time. You can also direct questions about the content to the editorial team and receive personalized responses. You do not need to cancel your demo access. The free access will end automatically. Advantages at a glanceSpecial Offer as Part of Your Free Demo Access:Select one of the 21 chapters from the GMP in Practice section of the GMP Compliance Adviser—we’ll grant you full access to it until the end of your trial period. This allows you to delve deeply into the topic that’s most relevant to your daily practice. Take this opportunity to experience the in-depth technical content, practical explanations, and comprehensive expert knowledge the GMP Compliance Adviser has to offer—and see the tangible added value it brings to your work.

delivery immediately after receipt of payment
€0.00 net excl. VAT